294 related articles for article (PubMed ID: 33750196)
1. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
[TBL] [Abstract][Full Text] [Related]
2. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
[TBL] [Abstract][Full Text] [Related]
3. Tipifarnib as a Precision Therapy for
Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
[TBL] [Abstract][Full Text] [Related]
4.
Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
[TBL] [Abstract][Full Text] [Related]
5. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
Lee HW; Sa JK; Gualberto A; Scholz C; Sung HH; Jeong BC; Choi HY; Kwon GY; Park SH
Clin Cancer Res; 2020 Oct; 26(19):5113-5119. PubMed ID: 32636318
[TBL] [Abstract][Full Text] [Related]
8. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ; Guenette JP; Chau NG; Sayehli CM; Wilhelm C; Metcalf R; Wong DJ; Brose M; Razaq M; Pérez-Ruiz E; Cohen EEW; Aggarwal R; Scholz C; Gualberto A; Ho AL
Cancer; 2020 Sep; 126(17):3972-3981. PubMed ID: 32557577
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
10. Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
Shu L; Wang D; Nannapaneni S; Sun Y; Griffith CC; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; Chen ZG; Saba NF
Oral Oncol; 2021 Nov; 122():105546. PubMed ID: 34700281
[TBL] [Abstract][Full Text] [Related]
11. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
Ben Yahia H; Petit FM; Saada-Bouzid E
Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
[TBL] [Abstract][Full Text] [Related]
12. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.
Wang J; Al-Majid D; Brenner JC; Smith JD
Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
14. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
Desilets A; Ho AL
Cancer J; 2022 Sep-Oct 01; 28(5):363-368. PubMed ID: 36165724
[TBL] [Abstract][Full Text] [Related]
15. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
[TBL] [Abstract][Full Text] [Related]
16. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Kochanny SE; Worden FP; Adkins DR; Lim DW; Bauman JE; Wagner SA; Brisson RJ; Karrison TG; Stadler WM; Vokes EE; Seiwert TY
Cancer; 2020 May; 126(10):2146-2152. PubMed ID: 32073648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
